2021-05-05T08:57:34-05:00 2020-06-30 366055558 GRANT THORNTON LLP 200 S ORANGE AVENUE SUITE 2050 ORLANDO FL 32801 990 2019-07-01 592451713 H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC HLEE 8137454673 12902 MAGNOLIA DRIVE TAMPA FL 33612 YVETTE M LYONS TREMONTI EVP/CFAO 8137457862 2021-05-05 1 MICHELE N MELCHIOR P00488037 4074815100 2019 2022-09-23 18:48:47Z DR PATRICK HWU 12902 MAGNOLIA DRIVE TAMPA FL 33612 430590122 0 X WWW.MOFFITT.ORG X 1984 FL TO PROMOTE AND SUPPORT THROUGH RESEARCH, MANAGEMENT AND OTHER MEANS OF SUPPORT. 25 25 2391 349 17324175 10846860 161127950 180471501 19263745 21623423 3755710 -1449863 4305886 2564420 188453291 203209481 780671 505564 0 0 128731739 140826199 0 0 0 92186877 96534299 221699287 237866062 -33245996 -34656581 992029257 1582286412 434049179 879938884 557980078 702347528 X SEE SCHEDULE OTO PROMOTE AND SUPPORT H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE LIFETIME CANCER SCREENING CENTER, AND H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION THROUGH RESEARCH, MANAGEMENT, AND OTHER MEANS OF SUPPORT. 0 0 160505638 505564 20001596 SEE SCHEDULE O FOR CONTINUATIONTHE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. IS ARECOGNIZED LEADER IN FOCUSED, INNOVATIVE CANCER RESEARCH, A MAJORREGIONAL ONCOLOGY REFERRAL CENTER, AND A NATIONAL CANCER INSTITUTE DESIGNATED COMPREHENSIVE CANCER CENTER.BASED ON ITS SINGULAR MISSION - TO CONTRIBUTE TO THE PREVENTION ANDCURE OF CANCER - THE CANCER CENTER'S RESEARCH ACTIVITIES RELATEPRIMARILY TO THE AREAS OF BASIC SCIENCE, CANCER PREVENTION AND CONTROL, TRANSLATIONAL SCIENCE, PRE-CLINICAL AND CLINICAL INVESTIGATIONS, AND PROVIDING MANAGEMENT AND OTHER SUPPORT SERVICES AS THE SOLE CORPORATE MEMBER AND PARENT FOR THE FOLLOWING SUBSIDIARY CORPORATIONS:H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. (THE HOSPITAL) WHICH PROVIDES MEDICAL AND HOSPITAL CARE, MEDICAL EDUCATION AND TRAINING, AND CLINICAL (PATIENT-RELATED) RESEARCH IN MAINTAINING HEALTH, AND PREVENTING, DETECTING, AND TREATING CANCER;H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE LIFETIME CANCERSCREENING CENTER, INC. (MOFFITT MEDICAL GROUP) WHICH EMPLOYS ANDMANAGES PHYSICIANS AND OTHER MEDICAL PROFESSIONALS WHO STAFF THEHOSPITAL, AND PROVIDE CLINICAL RESEARCH SERVICES TO THE CANCER CENTER; AND H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION, INC. (THE FOUNDATION) WHICH IS THE PRINCIPAL FUND-RAISING ORGANIZATION FOR THE CANCER CENTER AND ITS SUBSIDIARIES.THE CANCER CENTER'S MULTIDISCIPLINARY CLINICAL PROGRAM STRUCTURE AND OPEN LABORATORY ARCHITECTURE PROVIDE AN ENVIRONMENT CONDUCIVE FOR TRAINING FUTURE SCIENTIFIC AND CLINICAL LEADERS IN ONCOLOGY, AND REFLECT THE CANCER CENTER'S COMMITMENT TO COLLABORATION IN ALL ASPECTS OF CANCER RESEARCH. 160505638 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 360 0 1 2391 1 1 1 0 0 0 0 0 0 0 0 0 1 0 X 25 25 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 X YVETTE M LYONS TREMONTI 8137457862 12902 MAGNOLIA DR TAMPA FL 33612 ALAN F LIST PRES/CEO 55.00 2.00 X 1846432 0 444247 JOHN A KOLOSKY EVP COO 24.00 32.00 X 998205 0 960228 THOMAS A SELLERS EVP CNT DIR, DIR-MRI 55.00 1.00 X 996232 0 411164 YVETTE M LYONS TREMONTI EVP-CFAO & ASST TREASURER 22.00 36.00 X 964941 0 321875 G DOUGLAS LETSON EVP-PIC 18.00 37.00 X 0 960289 256848 L DAVID DE LA PARTE EVP GEN COUNS & ASST SEC 22.00 36.00 X 794823 0 328756 LYNN MOSCINSKI FRM CHIEF ACADEMIC OFF TO 6/28/19 0.00 50.00 X 0 638072 207308 JONATHAN ZAGER CHIEF ACADEMIC OFFICER AS OF 6/30/19 15.00 40.00 X 25417 603614 126366 JAMES J MULAY ACD TRANSLATIONAL RSCH 50.00 2.00 X 656777 0 79961 JOHN CLEVELAND EVP-DIR MOFFITT RSH INST & CNTR DIR 55.00 0.00 X 556384 0 144204 ROBERT J GILLIES PL CHAIR RSCH BASIC SCIENCE 50.00 0.00 X 441162 0 258283 WJ WILSON VP GOVT RELATIONS 55.00 0.00 X 409140 0 277361 ANNA GIULIANO DEPT CHAIR CUTANEOUS ONC 50.00 0.00 X 404186 0 261855 MARIANA BUGALLO-MUROS VP CHIEF HR OFFICER 55.00 0.00 X 484791 0 173154 DANA E ROLLISON VP CHIEF DATA OFFICER 55.00 0.00 X 450593 0 205396 BRIAN SPRINGER VP RESEARCH ADMINISTRATION 55.00 0.00 X 499233 0 116576 B LEE GREEN VP DIVERSITY, PR & STRAT COMM 55.00 0.00 X 417035 0 190127 DIANE HAMMON VP CHIEF STRATEGY OFFICER 55.00 0.00 X 443388 0 147553 JOANNA WEISS VP FINANCE 30.00 25.00 X 418125 0 138073 KAREN FIELDS MEDICAL DIR CLINICAL PATHWAYS 50.00 0.00 X 421538 0 82689 SHELLEY TWOROGER ACD POPULATION SCIENCE 50.00 0.00 X 414405 0 61544 DONALD FUTRELL VP PLAN, DESIGN & CONS 55.00 0.00 X 396763 0 76177 CHARLES FLETCHER VP DEPUTY GENERAL COUNSEL 55.00 0.00 X 359736 0 53120 JENNIFER GREENMAN VP & CIO TO 7/19/2019 55.00 0.00 X 237928 0 166501 S DOMINIC SERAPHIN VP STRAT ALLIANCE & NTWK TO 5/15/20 30.00 25.00 X 338688 0 50737 ROGER B BRADLEY VP FAC & SUP SVCS 55.00 0.00 X 165821 0 10288 EDMONDO ROBINSON SVP CHIEF DIGITAL INNO AS OF 12/9/19 55.00 1.00 X 80385 0 23 BENJAMIN H HILL III ESQ DIRECTOR, SECRETARY/TREASURER 1.00 1.00 X X 0 0 0 BETH A HOUGHTON DIRECTOR, VICE CHAIR 1.00 1.00 X X 0 0 0 ROBERT ROTHMAN DIRECTOR, IMMED PAST CHAIR 1.00 1.00 X X 0 0 0 TIMOTHY J ADAMS DIRECTOR, CHAIR/INTERIM CEO 1.00 2.00 X X 0 0 0 ALAN LEVINE DIRECTOR 1.00 0.00 X 0 0 0 ALLISON ADAMS DIRECTOR 1.00 0.00 X 0 0 0 ANGELA BIEVER DIRECTOR 1.00 0.00 X 0 0 0 CARLOS ALFONSO DIRECTOR 1.00 0.00 X 0 0 0 CECELIA FERMAN DIRECTOR 1.00 0.00 X 0 0 0 EDWARD C DROSTE DIRECTOR 1.00 1.00 X 0 0 0 EDWARD DEBARTOLO DIRECTOR 1.00 0.00 X 0 0 0 FRANCISCO SANCHEZ DIRECTOR 1.00 0.00 X 0 0 0 GEOFFREY M DUYK PHD MD DIRECTOR 1.00 1.00 X 0 0 0 JOHN RAMIL DIRECTOR 1.00 0.00 X 0 0 0 JOHN TOMLIN DIRECTOR 1.00 0.00 X 0 0 0 JOSEPH CABALLERO DIRECTOR 1.00 2.00 X 0 0 0 LIZ SMITH DIRECTOR 1.00 0.00 X 0 0 0 PAMELA STEWART DIRECTOR 1.00 0.00 X 0 0 0 REGINALD GOINS DIRECTOR 1.00 1.00 X 0 0 0 STEVEN CURRALL DIRECTOR 1.00 0.00 X 0 0 0 THE HON CARL CARPENTER DIRECTOR 1.00 0.00 X 0 0 0 THE HON H LEE MOFFITT ESQ DIRECTOR 1.00 2.00 X 0 0 0 THE HON JAMES T HARGRETT ESQ DIRECTOR 1.00 0.00 X 0 0 0 THE HON JOHN A GRANT ESQ DIRECTOR 1.00 0.00 X 0 0 0 VALERIE GODDARD DIRECTOR 1.00 1.00 X 0 0 0 ELIZABETH LINDSAY-WOOD VP-CIO AS OF 5/4/20 55.00 0.00 X 0 0 0 HENRY REYES VP-PARTNERSHIP DEV AS OF 5/14/20 55.00 0.00 X 0 0 0 13222128 2201975 5550414 321 1 1 0 BIRDSALL VOSS & ASSOCIATES 250 W COVENTRY COURT STE 300 MILWAUKEE WI 53217 MARKETING SERVICES 7312303 SHUMAKER LOOP & KENDRICK LLP 101 E KENNEDY BLVD STE 2800 TAMPA FL 33602 LEGAL SERVICES 2659569 BARR & BARR INC 460 W 34TH ST FL 10 NEWYORK NY 10001 PROFESSIONAL SERVICES 2546791 SODEXO INC & AFFILIATES 9801 WASHINGTONIAN BLVD GAITHERSBURG MD 20878 FOOD MANAGEMENT 2395754 MODUS DIRECT LLC 1343 MAIN ST STE 600 SARASOTA FL 34236 MARKETING SERVICES 1972500 86 30236971 92000696 58233834 7838062 180471501 CELL THERAPY PRODUCTS 541700 10575198 10575198 MHS/BAYCARE/ADVENT MANAGEMENT SRV 541610 5998676 5998676 CORE LAB REVENUE 541900 2502385 2502385 M2GEN SERVICE REVENUE 541900 1606275 1606275 INTERNATIONAL COLLAB 541700 500000 500000 440889 440889 21623423 5887341 5887341 275325 275325 125200 5200 120000 120000 120000 219762912 227366515 8926 -7603603 -8926 -7612529 -7612529 PARKING 531120 900045 10099 889946 SUPPORT ACCOUNTS REIMBURSEMENTS 900099 758853 758853 LICENSE FEES 541700 291471 291471 494051 120202 373849 2444420 203209481 4824874 17324175 588931 X 505564 505564 11086662 9091063 1995599 108899895 72925806 35974089 4499662 3009856 1489806 9308676 7045607 2263069 7031304 4703924 2327380 2837537 2837537 57635 57635 140094 140094 809471 809471 28785217 13169285 15615932 1944782 46701 1898081 18604698 13490153 5114545 6284513 6284513 4337659 479435 3858224 1748454 856457 891997 1366183 1366183 11928511 11928511 171492 171492 ALLOC OF INTERCO EXP 0 22795662 -22795662 SUBCONTRACTS 5640365 5640365 INCOME TAX EXPENSE 3046300 3046300 CORE LAB EXPENSES 2170885 2170885 6660503 4574875 2085628 237866062 160505638 77360424 0 155959306 245490296 143257926 496265103 11932243 20089365 14650692 13392531 969927982 475788886 421529754 494139096 178121175 222114858 500100 500100 66078061 90295064 992029257 1582286412 121459664 144793959 3278941 2512108 297753849 702490577 11556725 30142241 434049179 879938884 X 486895847 635201170 71084231 67146358 557980078 702347528 992029257 1582286412 X -34656581 179024031 X 0 1 X 1 1 1 X 132852458 142592916 151923266 161127950 180471501 768968091 132852458 142592916 151923266 161127950 180471501 768968091 768968091 3014450 2862859 4551933 6650393 6162666 23242301 15896 2586085 4703817 6715669 10846860 24868327 3759373 2506415 27639537 4037784 2314119 40257228 857335947 26456419 0.89690 0.88910 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: LICENSE FEES - 2015 AMOUNT: $ 282,908. 2016 AMOUNT: $ 546,788. 2017 AMOUNT: $ 26,131,592. 2018 AMOUNT: $ 2,496,454. 2019 AMOUNT: $ 291,471. PARKING - 2015 AMOUNT: $ 1,043,690. 2016 AMOUNT: $ 1,004,190. 2017 AMOUNT: $ 916,930. 2018 AMOUNT: $ 950,775. 2019 AMOUNT: $ 889,946. EYE INSTITUTE REIMBURSEMENT - 2015 AMOUNT: $ 127,560. 2016 AMOUNT: $ 146,619. 2017 AMOUNT: $ 128,217. 2018 AMOUNT: $ 36,832. 2019 AMOUNT: $ 0. LEASES - 2015 AMOUNT: $ 48,351. 2016 AMOUNT: $ 21,551. 2017 AMOUNT: $ 69,570. 2018 AMOUNT: $ 66,885. 2019 AMOUNT: $ 32,016. STAFF RETAIL SERVICES - 2015 AMOUNT: $ 41,892. 2016 AMOUNT: $ 51,364. 2017 AMOUNT: $ 59,077. 2018 AMOUNT: $ 45,748. 2019 AMOUNT: $ 33,888. SETTLEMENT - 2016 AMOUNT: $ 410,360. 2017 AMOUNT: $ 204,624. 2019 AMOUNT: $ 0. SUPPORT ACCOUNTS - 2015 AMOUNT: $ 415,730. 2016 AMOUNT: $ 232,370. 2017 AMOUNT: $ 15,078. 2018 AMOUNT: $ 179,614. 2019 AMOUNT: $ 758,853. REBATES/REFUNDS - 2015 AMOUNT: $ 116,048. 2016 AMOUNT: $ 85,728. 2017 AMOUNT: $ 83,127. 2018 AMOUNT: $ 247,557. 2019 AMOUNT: $ 171,326. INTEREST FROM CONTROLLED ORG - 2015 AMOUNT: $ 152,860. PREMIER PARTNERSHIP - 2015 AMOUNT: $ 924,975. REV RECOG OF PRIOR YEAR LIABILITY - 2015 AMOUNT: $ 584,843. MISC - 2015 AMOUNT: $ 20,516. 2016 AMOUNT: $ 7,445. 2017 AMOUNT: $ 31,322. 2018 AMOUNT: $ 13,919. 2019 AMOUNT: $ 11,786. REIMBURSEMENT OF EXPENSES - 2019 AMOUNT: $ 55,568. PATENT EXPENSE REIMBURSEMENT - 2019 AMOUNT: $ 69,265. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 0 1 5245 1 5661 0 1 211176 1 9874 1 11304 243260 0 PART II-B, LINE 1: THE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. AND ITS THREE NON-PROFIT SUBSIDIARY CORPORATIONS ("CORPORATION") WERE CREATED TO GOVERN AND OPERATE THE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE ("INSTITUTE") PURSUANT TO SECTION 1004.43, FLORIDA STATUTES. AMONG OTHER THINGS, SECTION 1004.43, FLORIDA STATUTES PROVIDES: (1) THAT THE CORPORATION SHALL ENTER INTO AN AGREEMENT WITH THE STATE BOARD OF EDUCATION FOR THE UTILIZATION OF FACILITIES ON THE CAMPUS OF THE UNIVERSITY OF SOUTH FLORIDA; (2) THAT THE CORPORATION SUBMIT ANNUAL POST AUDITS OF ITS FINANCIAL ACCOUNTS TO THE AUDITOR GENERAL OF THE STATE OF FLORIDA AND THE BOARD OF GOVERNORS FOR THEIR REVIEW; AND (3) THAT THE CORPORATION'S CEO REPORT TO THE BOARD OF GOVERNORS OR ITS DESIGNEE AND PROVIDE COPIES OF THE INSTITUTE'S ANNUAL REPORT TO THE GOVERNOR OF THE STATE OF FLORIDA, THE CABINET, THE PRESIDENT OF THE SENATE, THE SPEAKER OF THE HOUSE AND THE CHAIR OF THE BOARD OF GOVERNORS. ALTHOUGH THE CORPORATION IS A PRIVATE ENTITY, IT IS NONETHELESS SUBJECT TO THE STATE OF FLORIDA'S PUBLIC RECORDS AND THE PUBLIC MEETINGS LAWS. THE CORPORATION ALSO RELIES ON ANNUAL APPROPRIATIONS BY THE LEGISLATURE OF THE STATE OF FLORIDA AND GRANTS FROM VARIOUS LOCAL, STATE AND FEDERAL AGENCIES FOR OPERATION AND MAINTENANCE OF ITS FACILITIES AND FOR SPECIFIC RESEARCH AND CLINICAL PROGRAMS. FOR THESE REASONS, THE CORPORATION FROM TIME TO TIME ENGAGES LOBBYISTS AND OTHER CONSULTANTS; (1) TO ASSIST IT IN COMPLYING WITH ITS REPORTING REQUIREMENTS TO THE STATE OF FLORIDA UNDER SECTION 1004.43, FLORIDA STATUTES; (2) TO MONITOR LEGISLATIVE AND EXECUTIVE BRANCH ACTION AT LOCAL, STATE AND FEDERAL LEVELS OF GOVERNMENT WHICH IMPACT ITS OPERATION AND THE FULFILLMENT OF ITS MISSION; AND (3) TO INFLUENCE LEGISLATION IN FURTHERANCE OF ITS MISSION IN THE AREAS OF CANCER RESEARCH AND TREATMENT, THE TEACHING AND TRAINING OF HEALTH CARE PROFESSIONALS AND COMMUNITY EDUCATION AND OUTREACH ACTIVITIES. THE CORPORATION DOES NOT ENGAGE IN ANY ACTIVITIES TO SUPPORT OR OPPOSE ANY CANDIDATE FOR PUBLIC OFFICE. PART II-B, LINE 1I, OTHER ACTIVITIES THE OTHER ACTIVITIES AMOUNT LISTED ON LINE 1I IS COMPRISED OF EXPENSES RELATED TO ORCHESTRATING CONTACT BETWEEN GRASSROOTS SUPPORTERS (WHO ARE VOLUNTEERS) AND ELECTED OFFICIALS TO PROMOTE THE INSTITUTION'S LEGISLATIVE OBJECTIVES. 26107905 26107905 566748849 233628528 333120321 6020972 3179040 2841932 332118871 238981318 93137553 38931385 38931385 494139096 INTEREST IN NET ASSETS OF FOUNDATION 46726058 RECEIVABLES FROM CONTROLLED ORGS 10854833 OTHER RECEIVABLES 3054807 OTHER ASSETS 299618 RIGHT OF USE ASSET-OPERATING 29359748 90295064 LEASE OBLIGATIONS 29530390 OTHER LIABILITIES 611851 30142241 X PART X, LINE 2: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. DID NOT HAVE ANY UNCERTAIN POSITIONS IN ITS AUDITED FINANCIAL STATEMENTS. THE ASC-740 FOOTNOTE READS AS FOLLOWS: THE CANCER CENTER RECOGNIZES A TAX POSITION AFTER DETERMINING THAT A RELEVANT TAX AUTHORITY WOULD MORE LIKELY THAN NOT (GREATER THAN 50% LIKELIHOOD) SUSTAIN THE POSITION FOLLOWING AN AUDIT AND RECORDS THESE BENEFITS AT THE AMOUNT MOST LIKELY TO BE REALIZED, ASSUMING A REVIEW BY TAX AUTHORITIES HAVING ALL RELEVANT INFORMATION AND APPLYING CURRENT CONVENTIONS. 1 H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE HOSPITAL INC 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238634 501C3 29915 INTERCOMPANY SUPPORT M2GEN INC 10902 N MCKINLEY DRIVE TAMPA FL 33612 208486180 C CORP 47942 INTERCOMPANY SUPPORT TAMPA INNOVATON ALLIANCE INC 3100 E FLETCHER AVE TAMPA FL 33613 611692291 501C6 100000 SPONSORSHIP HILLSBOROUGH EDUCATION FDN 2306 N HOWARD AVE TAMPA FL 33607 592883361 501C3 50000 SPONSORSHIP COPPERHEAD CHARITIES INC 36750 US HWY 19 N PALM HARBOR FL 34684 592319162 501C3 31550 SPONSORSHIP LEGENDS FOOTBALL INC 19046 BRUCE B DOWNS BLVD 108 TAMPA FL 33647 831923297 501C3 25000 SPONSORSHIP LEUKEMIA & LYMPHOMA SOCIETY 3505 E FRONTAGE RD STE 145 TAMPA FL 33607 135644916 501C3 25000 SPONSORSHIP AMERICAN CANCER SOCIETY INC 250 WILLIAMS STREET ATLANTA GA 30303 131788491 501C3 19000 SPONSORSHIP BIOFLORIDA INC 6742 FOREST HILL BLVD STE 256 WEST PALM BEACH FL 33413 593436638 501C6 11000 SPONSORSHIP KAY YOW CANCER FUND 5121 KINGDOM WAY STE 305 RALEIGH NC 27607 261789695 501C3 10000 SPONSORSHIP USF ALUMNI ASSOCIATION 4202 EAST FOWLER AVE ALC 100 TAMPA FL 33620 237357236 501C3 10000 SPONSORSHIP POYNTER INSTITUTE 801 THIRD STREET N ST PETERSBURG FL 33701 591630423 501C3 7500 SPONSORSHIP 9 3 PART I, LINE 2: THE SCHEDULE I, PART II, GRANTS LISTED AS SPONSORSHIPS ARE APPROVED THROUGH THE CHECK REQUEST PROCESS. BECAUSE OF THE NATURE OF THE GRANTS, THE GRANT USE IS NOT MONITORED SINCE THEY ARE GIVEN TO THE ORGANIZATION FOR A SPECIFIC PURPOSE OR EVENT. THE GRANTS LISTED AS INTERCOMPANY SUPPORT ARE ONLY MADE TO RELATED ORGANIZATIONS TO SUPPORT THEIR OPERATIONS. X 0 0 X X X X 0 1 0 0 0 1 1 0 0 ALAN F LIST PRES/CEO 962345 0 679006 0 205081 0 411874 0 39741 0 2298047 0 0 0 JOHN A KOLOSKY EVP COO 637453 0 272161 0 88591 0 935088 0 32263 0 1965556 0 0 0 THOMAS A SELLERS EVP CNT DIR, DIR-MRI 643501 0 269995 0 82736 0 386765 0 31426 0 1414423 0 0 0 YVETTE M LYONS TREMONTI EVP-CFAO & ASST TREASURER 628335 0 264605 0 72001 0 292033 0 36369 0 1293343 0 0 0 G DOUGLAS LETSON EVP-PIC 0 630149 0 267799 0 62341 0 228820 0 34724 0 1223833 0 0 L DAVID DE LA PARTE EVP GEN COUNS & ASST SEC 528721 0 223021 0 43081 0 301619 0 34961 0 1131403 0 0 0 LYNN MOSCINSKI FRM CHIEF ACADEMIC OFF TO 6/28/19 0 546741 0 75154 0 16177 0 16177 0 183598 0 837847 0 0 JONATHAN ZAGER CHIEF ACADEMIC OFFICER AS OF 6/30/19 23428 466569 1923 130912 66 6133 73014 24760 4350 29471 102781 657845 0 0 JAMES J MULAY ACD TRANSLATIONAL RSCH 441776 0 155559 0 59442 0 59525 0 31232 0 747534 0 0 0 JOHN CLEVELAND EVP-DIR MOFFITT RSH INST & CNTR DIR 387892 0 139470 0 29022 0 113962 0 45242 0 715588 0 0 0 ROBERT J GILLIES PL CHAIR RSCH BASIC SCIENCE 350848 0 82322 0 7992 0 236294 0 22906 0 700362 0 0 0 WJ WILSON VP GOVT RELATIONS 268799 0 96256 0 44085 0 252909 0 34122 0 696171 0 0 0 ANNA GIULIANO DEPT CHAIR CUTANEOUS ONC 349609 0 46514 0 8063 0 234263 0 30536 0 668985 0 0 0 MARIANA BUGALLO-MUROS VP CHIEF HR OFFICER 354258 0 127051 0 3482 0 153628 0 32761 0 671180 0 0 0 DANA E ROLLISON VP CHIEF DATA OFFICER 311140 0 110256 0 29197 0 188657 0 22643 0 661893 0 0 0 BRIAN SPRINGER VP RESEARCH ADMINISTRATION 356352 0 127051 0 15830 0 90271 0 34713 0 624217 0 0 0 B LEE GREEN VP DIVERSITY, PR & STRAT COMM 292162 0 102204 0 22669 0 164765 0 34277 0 616077 0 0 0 DIANE HAMMON VP CHIEF STRATEGY OFFICER 311322 0 111282 0 20784 0 119961 0 38062 0 601411 0 0 0 JOANNA WEISS VP FINANCE 288869 0 103951 0 25305 0 106450 0 39633 0 564208 0 0 0 KAREN FIELDS MEDICAL DIR CLINICAL PATHWAYS 333685 0 68261 0 19592 0 63810 0 26885 0 512233 0 0 0 SHELLEY TWOROGER ACD POPULATION SCIENCE 305791 0 107635 0 979 0 50366 0 19752 0 484523 0 0 0 DONALD FUTRELL VP PLAN, DESIGN & CONS 277446 0 101156 0 18161 0 54648 0 31364 0 482775 0 0 0 CHARLES FLETCHER VP DEPUTY GENERAL COUNSEL 263897 0 94502 0 1337 0 24728 0 33756 0 418220 0 0 0 JENNIFER GREENMAN VP & CIO TO 7/19/2019 189951 0 0 0 47977 0 153288 0 16679 0 407895 0 0 0 S DOMINIC SERAPHIN VP STRAT ALLIANCE & NTWK TO 5/15/20 215818 0 83637 0 39233 0 19613 0 41301 0 399602 0 0 0 ROGER B BRADLEY VP FAC & SUP SVCS 144538 0 20000 0 1283 0 476 0 16584 0 182881 0 0 0 PART I, LINE 1A INSTITUTE PAYS MEMBERSHIP DUES TO A SOCIAL CLUB FOR DAVID DE LA PARTE, W.J. WILSON, AND JAMES MULAY. THE AMOUNT PAID IS SUBSEQUENTLY ADDED TO TAXABLE WAGES FOR THE RESPECTIVE INDIVIDUAL. PART I, LINE 1B: PAYMENTS MADE FOR SOCIAL CLUB DUES ARE INITIALLY APPROVED BY EXECUTIVE LEADERSHIP AND HUMAN RESOURCES AND REVIEWED/APPROVED BY THE JOINT EXECUTIVE COMPENSATION AND BENEFITS COMMITTEE (JE&BC), APPOINTED BY THE BOARD TO APPROVE SUCH PAYMENTS AND ASSOCIATED AMOUNTS. PART I, LINE 4B TO BE ELIGIBLE TO PARTICIPATE IN THE 457(F) NON-QUALIFIED SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN (SERP), PARTICIPANTS MUST ELECT TO CONTRIBUTE AT LEAST 10% ACROSS THE 403(B) AND 457(B) PLANS, AND ARE VESTED AFTER 10 YEARS OF SERVICE. LUMP SUM DISTRIBUTIONS FROM THE ACCOUNT ARE MADE UPON NORMAL RETIREMENT OR TERMINATION. BELOW ARE INDIVIDUALS LISTED ON MOFFITT'S 2019 FORM 990 PART VII, SECTION A, THAT PARTICIPATED IN THE 457(F) SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN AND THEIR RESPECTIVE AMOUNTS OF COMPENSATION CONSTRUCTIVELY RECEIVED IN TAX YEAR 2019 FROM THE PLAN: ALAN F. LIST - $118,229.24 JOHN A. KOLOSKY - $56,144 THOMAS A. SELLERS - $50,487 YVETTE M. LYONS TREMONTI - $47,887 G. DOUGLAS LETSON - $54,918 L. DAVID DE LA PARTE - $38,187 LYNN MOSCINSKI - $1,500 JONATHAN ZAGER - $4,500 JAMES J. MULAY - $34,925 JOHN CLEVELAND - $0 ROBERT J. GILLIES - $1,500 W.J. WILSON - $13,802 ANNA GIULIANO - $1,500 MARIANA BUGALLO-MUROS - $0 DANA E. ROLLISON - $22,111 BRIAN SPRINGER - $0 B. LEE GREEN - $14,714 DIANE HAMMON - $19,169 JOANNA WEISS - $18,056 KAREN FIELDS - $1,500 SHELLEY TWOROGER - $0 DONALD FUTRELL - $13,108 CHARLES FLETCHER - $0 JENNIFER GREENMAN - $0 PART I, LINE 6 IN GENERAL, INCENTIVE COMPENSATION IS BASED ON A PERCENTAGE OF MOFFITT'S NET OPERATING INCOME AND ACHIEVEMENT AGAINST SPECIFIC ORGANIZATIONAL GOALS, DIVISIONAL AND/OR INDIVIDUAL GOALS, PROVIDED A CERTAIN NET OPERATING INCOME THRESHOLD IS MET. A HILLSBOROUGH CTY INDUSTRIAL DEV AUTHORITY 591293512 NONEAVAIL 2015-10-06 9750000 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 B HILLSBOROUGH CTY INDUSTRIAL DEV AUTHORITY 591293512 NONEAVAIL 2015-10-22 8690000 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 C CITY OF TAMPA 591101138 875282BE4 2012-09-19 144692131 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 D CITY OF TAMPA 591101138 875161BN0 2012-11-29 39972900 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 A 9774674 8652651 1122023 2010 1 0 1 1 B 4610000 8711992 7711953 1000039 2010 1 0 1 1 C 29045000 146140274 17913907 1176163 126534872 515332 2016 1 0 1 1 D 11515000 40685404 40400519 284885 2012 1 0 1 1 A 0 1 1 1 0 0 0 1 B 0 1 1 1 0 0 0 1 C 0 1 1 1 0 0 0 1 A 0 0 0 1 1 0 0 0 1 B 0 0 0 1 1 0 0 0 1 C 0 0 0 1 0 0 0 0 1 D 0 0 0 1 0 0 0 0 1 A 1 B 1 C 1 D 1 FORM 990, SCHEDULE K, PART IA COLUMN (F) REPLACEMENT BONDS 2015A WERE ISSUED FOR A PORTION OF THE OUTSTANDING PRINCIPAL BALANCE OF THE 2010A SERIES AND USED FOR: 1)RETIRING A PORTION OF THE 2010A BOND. 2)FINANCING AND REFINANCING CERTAIN OTHER CAPITAL COSTS PREVIOUSLY INCURRED BY THE HOSPITAL WITH RESPECT TO SUCH PROJECTS. FORM 990, SCHEDULE K, PART IB COLUMN (F) REPLACEMENT BONDS 2015B WERE ISSUED FOR A PORTION OF THE OUTSTANDING PRINCIPAL BALANCE OF THE 2010A SERIES AND USED FOR: 1)RETIRING A PORTION OF THE 2010A BOND. 2)FINANCING AND REFINANCING CERTAIN OTHER CAPITAL COSTS PREVIOUSLY INCURRED BY THE HOSPITAL WITH RESPECT TO SUCH PROJECTS. FORM 990, SCHEDULE K, PART IC COLUMN (F) PROCEEDS FROM THE 2012A BONDS WERE USED FOR: 1) ACQUISITION, CONSTRUCTION, FURNISHING AND EQUIPPING OF THE MULTI-STORY MCKINLEY CLINICAL RESEARCH FACILITY AND INFRASTRUCTURE THAT WILL CONTAIN AN AMBULATORY SURGERY CENTER, PROCEDURE SUITES, CLINICS, IMAGING, INFUSION, SCREENING AND DRY LAB RESEARCH. 2)CONSTRUCTION, RENOVATION, AND EQUIPPING CLINICAL AND RESEARCH FACILITIES INCLUDING ADDITIONAL BED CAPACITY, OPERATING SUITES AND ASSOCIATED FACILITIES AND INFRASTRUCTURE. 3) A PORTION OF THE 2012A PROCEEDS WAS USED TO CURRENT REFUND 2002A AND 2002B SERIES BONDS, BOTH ISSUED NOVEMBER 14, 2002. FORM 990, SCHEDULE K, PART ID COLUMN (F) 1) SERIES 2012B WERE PROCEEDS USED TO CURRENT REFUND SERIES 1999A AND 2002C BONDS, ISSUED MARCH 25, 1999 AND NOVEMBER 14, 2002 RESPECTIVELY. FORM 990, SCHEDULE K, PART IE COLUMN (F) PROCEEDS OF THE 2016A BOND ISSUANCE WILL BE USED TO PURCHASE LAND AND BUILDING ON USF CAMPUS AND AN ADDITIONAL MCKINLEY CAMPUS SITE FOR CONSTRUCTION OF RESEARCH AND RESEARCH SUPPORT FACILITIES, CLINICAL AND RESEARCH SUPPORT OFFICES, THE RELOCATION OF CHILD DEVELOPMENT CENTER, AND THE CONSTRUCTION OF RESEARCH LABS. FORM 990, SCHEDULE K, PART IF COLUMN (F) SERIES 2016B IS AN ADVANCE REFUNDING ON SERIES 2007A WHICH WAS USED TO: 1) FINANCE THE COST OF CONSTRUCTION AND EQUIPPING A FOUR STORY ADDITION TO THE MAIN CAMPUS OF THE HOSPITAL, TO INCLUDE 36 ADDITIONAL INPATIENT BEDS, RADIATION ONCOLOGY CLINIC PROGRAM EXPANSION WITH THE ADDITION OF TWO NEW VAULTS USED FOR STATE OF THE ART LINEAR ACCELERATORS, CLINICAL LAB AND PATHOLGY PROGRAM EXPANSION, APPROXIMATELY 40,000 GROSS SQUARE FEET OF FACULTY OFFICE SPACE, AND 1,000 SPACE PARKING GARAGE. 2) FINANCE THE COST OF VARIOUS BACKFILL AND REFURBISHMENT PROJECTS, INCLUDING THE ADDITION OF EIGHT INPATIENT BEDS IN EXISTING SPACE LOCATED AT THE INSTITUTE AND HOSPITAL. FORM 990, SCHEDULE K, PART IG COLUMN (F) PROCEEDS FROM THE 2020A (IN ADDITION TO THE 2020B) BONDS WILL BE USED FOR: 1) ACQUISITION, CONSTRUCTION, FURNISHING AND EQUIPPING OF VARIOUS MEDICAL AND RESEARCH FACILITIES CAPITAL PROJECTS INCLUDING HOSPITAL EXPANSION PROJECT. 2)VARIOUS FACILITIES, INFRASTRUCTURE SUPPORT, EQUIPMENT, FURNISHINGS, BACKFILL AND REFURBISHMENT PROJECTS. FORM 990, SCHEDULE K, PART IH COLUMN (F) PROCEEDS FROM THE 2020B (IN ADDITION TO 2020A) BONDS WILL BE USED FOR: 1) ACQUISITION, CONSTRUCTION, FURNISHING AND EQUIPPING OF VARIOUS MEDICAL AND RESEARCH FACILITIES CAPITAL PROJECTS INCLUDING HOSPITAL EXPANSION PROJECT. 2)VARIOUS FACILITIES, INFRASTRUCTURE SUPPORT, EQUIPMENT, FURNISHINGS, BACKFILL AND REFURBISHMENT PROJECTS. SCHEDULE K, PART IV, LINE 2C: MOFFITT CONTRACTS WITH THIRD PARTY TO ANNUALLY CALCULATE ARBITRAGE REBATES. NO REBATES ARE DUE. FORM 990, SCHEDULE K PART II THE DIFFERENCE BETWEEN ISSUE PRICE IN SCHEDULE K, PART I AND TOTAL PROCEEDS OF THE ISSUE IN PART II, LINE 2 FOR EACH ISSUE IS INVESTMENT EARNINGS WITH THE EXCEPTION OF THE 2012A SERIES WHICH INCLUDES THE ADDITION OF SINKING FUNDS IN THE AMOUNT OF $709,282 FROM THE SERIES 2002A AND 2002B. A CITY OF TAMPA 591101138 875146AQ5 2016-11-16 58742390 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 B CITY OF TAMPA 591101138 875161CE9 2016-11-03 93832926 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 C CITY OF TAMPA 591101138 875146BD3 2020-06-25 119978935 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 D CITY OF TAMPA 591101138 875161DD0 2020-06-25 302148464 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 A 4785000 60758511 594871 58147019 2016621 0 0 0 1 B 3425000 93840261 92778972 1061289 2010 1 0 1 1 C 119978935 994315 188785 118795835 0 0 0 1 D 302148464 1882947 11854877 288410640 0 0 0 1 A 0 0 0 0 0 0 1 B 0 0 0 0 0 0 1 C 0 0 0 0 0 0 1 D 0 0 0 0 0 0 1 A 0 0 0 1 0 0 0 0 1 B 0 0 0 1 0 0 0 0 1 C 0 0 0 1 0 0 0 0 1 D 0 0 0 1 0 0 0 0 1 A 1 B 1 C 1 D 1 X EQUIPMENT 27 7838062 PURCHASE PRICE 0 0 0 0 PART I, COLUMN (B): THE NUMBER ON LINE 25(B) REPRESENTS THE NUMBER OF CONTRIBUTIONS, NOT THE NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART VI, SECTION A, LINE 2 THE FOLLOWING DIRECTORS AND OFFICERS, THAT JOINTLY SERVE ON THE INSTITUTE AND A FOR-PROFIT RELATED ENTITY, QUALIFY AS HAVING A BUSINESS RELATIONSHIP. INSTITUTE & MOFFITT GENETICS CORPORATION (M2GEN): TIMOTHY J. ADAMS, INSTITUTE DIRECTOR & M2GEN DIRECTOR ROBERT ROTHMAN, INSTITUTE DIRECTOR & M2GEN DIRECTOR THOMAS A. SELLERS, INSTITUTE OFFICER & M2GEN DIRECTOR ALAN F. LIST, INSTITUTE OFFICER & M2GEN DIRECTOR EDMONDO ROBINSON, INSTITUTE OFFICER & M2GEN DIRECTOR LOUIS D. DE LA PARTE, INSTITUTE OFFICER & M2GEN OFFICER YVETTE M. LYONS TREMONTI, INSTITUTE OFFICER & M2GEN OFFICER INSTITUTE & MOFFITT TECHNOLOGIES CORPORATION (MTC): ALAN F. LIST, OFFICER INSTITUTE & MTC DIRECTOR JOHN A. KOLOSKY, OFFICER INSTITUTE & MTC DIRECTOR LOUIS D. DE LA PARTE, OFFICER INSTITUTE & MTC OFFICER YVETTE M. LYONS TREMONTI, OFFICER INSTITUTE & MTC OFFICER INSTITUTE & ONCOBAY CLINICAL (ONCOBAY): GEOFFREY M. DUYK, INSTITUTE DIRECTOR & ONCOBAY DIRECTOR LOUIS D. DE LA PARTE, INSTITUTE OFFICER & ONCOBAY DIRECTOR YVETTE M. LYONS TREMONTI, INSTITUTE OFFICER & ONCOBAY DIRECTOR BUSINESS RELATIONSHIP(S) BETWEEN DIRECTORS, OFFICERS OR KEY EMPLOYEE: DIRECTORS, ROBERT ROTHMAN AND TIMOTHY J. ADAMS, ARE INVESTORS OF LUMINA ANALYTICS, AN ORGANIZATION WITH WHICH MOFFITT DOES BUSINESS. FORM 990, PART VI, SECTION B, LINE 11B LINE 11B, PRIOR TO ELECTRONICALLY FILING FORM 990 (RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX), A COPY OF THE RETURN IS PROVIDED TO THE GOVERNING BODY, GIVING EACH BOARD MEMBER TIME TO REVIEW THE RETURN. BOARD MEMBERS HAVE THE OPPORTUNITY TO ASK QUESTIONS RELATED TO THE INFORMATION PROVIDED ON THE RETURN. THE MOFFITT'S FORM 990 IS ALSO PROVIDED TO THE CHIEF FINANCIAL OFFICER FOR REVIEW. BASED ON THE REVIEW ANY SUGGESTED COMMENTS OR CHANGES ARE DISCUSSED PRIOR TO SIGNING. FORM 990, PART VI, SECTION B, LINE 12C ON AN ANNUAL BASIS A PRESENTATION IS MADE TO RESEARCH BOARD MEMBERS TO REVIEW THE CONFLICT OF INTEREST POLICY AND PROCEDURES FOR DISCLOSING ANY POTENTIAL CONFLICTS. EACH DIRECTOR, OFFICER, COMMITTEE MEMBER, AND KEY EMPLOYEE SHALL COMPLETE A CONFLICT OF INTEREST DISCLOSURE CERTIFICATION VIA THE ELECTRONIC DISCLOSURE SYSTEM. ANY DIRECTOR, OFFICER, COMMITTEE MEMBER, OR KEY EMPLOYEE WHO REASONABLY BELIEVES THAT HE OR SHE MAY HAVE AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST MUST DISCLOSE THE EXISTENCE OF AND THE MATERIAL FACTS OF THE NATURE OF HIS/HER INTEREST ON THE FORM. THE ELECTRONIC FORM IS SUBMITTED TO THE CORPORATE COMPLIANCE OFFICE, WHICH REVIEWS THE FORMS, GATHERS ADDITIONAL RELEVANT INFORMATION WHERE NECESSARY, AND PREPARES A SUMMARY OF THE DISCLOSURES TO BE REVIEWED BY THE CONFLICT OF INTEREST WORK GROUP. IF A DIRECTOR OR COMMITTEE MEMBER DISCLOSES THAT HE/SHE HAS A POTENTIAL CONFLICT OF INTEREST AT A BOARD OR COMMITTEE MEETING, SUCH DIRECTOR OR COMMITTEE MEMBER MUST DISCLOSE THE NATURE OF THE INTEREST AND ANY RELATED INFORMATION AND RESPOND TO QUESTIONS AS MAY BE REQUIRED BY THE REMAINING MEMBERS. BASED ON THE INFORMATION DISCLOSED, THE REMAINING BOARD MEMBERS WILL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF A CONFLICT EXISTS THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER AN ALTERNATIVE TRANSACTION OR ARRANGEMENT THAT WOULD NOT GIVE RISE TO A CONFLICT IS EQUALLY ADVANTAGEOUS. IF AN ALTERNATIVE TRANSACTION IS NOT EQUALLY ADVANTAGEOUS THE DIRECTOR OR COMMITTEE MEMBER WHO IS THE SUBJECT OF THE CONFLICT SHALL NOT VOTE ON, NOR USE HIS/HER PERSONAL INFLUENCE ON, NOR PARTICIPATE IN DISCUSSIONS OR DELIBERATIONS WITH RESPECT TO THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 MOFFITT'S BOARD OF DIRECTORS HAS AN ESTABLISHED SUB-COMMITTEE, THE JOINT EXECUTIVE COMPENSATION & BENEFITS COMMITTEE (JEC&BC) THAT IS MADE UP ENTIRELY OF INDEPENDENT, OUTSIDE DIRECTORS. THIS COMMITTEE IS CHARGED WITH THE OVERSIGHT OF THE PERFORMANCE AND COMPENSATION OF MOFFITT EXECUTIVES AND DISQUALIFIED PERSONS. THESE POSITIONS INCLUDE THE CEO, EXECUTIVE VICE PRESIDENTS, SENIOR VICE PRESIDENTS, VICE PRESIDENTS AND DEPARTMENT CHAIRPERSONS. TO ACCOMPLISH ITS MISSION, THE COMMITTEE CAN AS NEEDED AND DOES AT ITS DISCRETION, ENGAGE OUTSIDE INDEPENDENT, OUTSIDE ADVISORS INCLUDING, BUT NOT LIMITED TO ATTORNEYS AND COMPENSATION CONSULTANTS. ON AN ANNUAL BASIS THE JEC&BC ENGAGES A NATIONALLY KNOWN, THIRD PARTY CONSULTING FIRM TO PROVIDE A DETAILED STUDY OF THE CASH COMPENSATION FOR EACH EXECUTIVE, DISQUALIFIED PERSON AND INDIVIDUAL IN KEY POSITIONS. THE CONSULTANT USES A VARIETY OF PUBLISHED SURVEYS COMPILED BY INDEPENDENT FIRMS TO PROVIDE THE SOURCE DATA FOR THE STUDY. USING FUNCTIONALLY COMPARABLE POSITIONS IN OTHER SIMILARLY SIZED, NOT-FOR-PROFIT AND FOR-PROFIT HEALTHCARE, ACADEMIC AND RESEARCH ORGANIZATIONS, THE CONSULTING FIRM PRODUCES A STUDY THAT COMPARES EACH DESIGNATED MOFFITT POSITION TO ITS APPROPRIATE MARKET EQUIVALENT. THE RESULTING DATA IS PROVIDED TO THE DIRECTOR OF COMPENSATION, WHO IS NOT INCLUDED IN THE EXECUTIVE OR DISQUALIFIED PERSON CATEGORIES, FOR USE IN THE FORMULATION OF RECOMMENDATIONS FOR COMPENSATION CHANGES TO MAINTAIN MARKET COMPETITIVENESS OR TO REWARD PERFORMANCE. THESE RECOMMENDATIONS ALONG WITH THE CONSULTANT'S COMPARABILITY DATA ARE PRESENTED TO THE JEC&BC FOR IT TO CONFIRM ITS REASONABLENESS, MAKE MODIFICATIONS AS IT DEEMS NECESSARY AND PROVIDE FINAL APPROVAL. EVERY THIRD YEAR THE INDEPENDENT CONSULTANT ANALYZES THE TOTAL EXECUTIVE COMPENSATION PROGRAM, USING THE SAME METHODOLOGY AS DESCRIBED ABOVE, THAT INCLUDES THE VALUE OF ALL BENEFITS AND PERQUISITES (CASH AND NON-CASH) PROVIDED AS COMPENSATION TO THE EXECUTIVES AND DISQUALIFIED PERSONS. THE PURPOSE OF THE ANALYSIS IS TO PROVIDE AN OPINION ON THE REASONABLENESS OF EACH OF THE INDIVIDUAL COMPENSATION COMPONENTS AND THE AGGREGATE COMPENSATION TOTAL. THIS MORE COMPREHENSIVE ANALYSIS IS PROVIDED TO THE JEC&BC FOR THEIR USE IN THE ANNUAL REVIEW PROCESS. MINUTES ARE KEPT AT EACH OF THESE ANNUAL MEETINGS DETAILING THE RECOMMENDATIONS PRESENTED AND THE DECISIONS MADE BY THE COMMITTEE. THESE MINUTES ARE PUBLISHED TO THE COMMITTEE AT THE NEXT MEETING AND REPORTED TO THE BOARD. FORM 990, PART VI, SECTION C, LINE 19 MOFFITT RESEARCH MAKES AVAILABLE TO THE PUBLIC THROUGH DAC BOND, THIRD PARTY VENDORS' WEBSITE AND MOFFITT'S WEBSITE THE CONSOLIDATED AUDITED FINANCIAL STATEMENTS. IN ADDITION FORM 990 IS MADE AVAILABLE ON GUIDESTAR AS WELL AS ON MOFFITT'S WEBSITE. ALL ORGANIZING AND GOVERNING DOCUMENTS SUCH AS FORM 1023, CONFLICTS OF INTEREST POLICY, AND BYLAWS AS WELL AS FORM 990 AND AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION B, LINE 16B: THE ORGANIZATION HAS ADOPTED A WRITTEN JOINT VENTURE PROCEDURE WITH WHICH IT COMPLIES, BUT HAS NOT BEEN BOARD APPROVED. PARENT/RESEARCH HAS ONE JOINT VENTURE AGREEMENT WITH PREMIER PURCHASING PARTNERS WHICH HAS BEEN IN EFFECT PRIOR TO 2008 AND RENEWED AT THE END OF 2014. FORM 990, PART IX, LINE 11G CONSULTING: PROGRAM SERVICE EXPENSES 1,130,508. MANAGEMENT AND GENERAL EXPENSES 1,685,166. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,815,674. FACULTY FEES AND COLLECTION EXPENSES: PROGRAM SERVICE EXPENSES -54,808. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES -54,808. PURCHASED SERVICES: PROGRAM SERVICE EXPENSES 12,093,585. MANAGEMENT AND GENERAL EXPENSES 13,930,766. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 26,024,351. FORM 990, PART IX, COLUMN (D): THERE ARE NO FUNDRAISING EXPENSES BECAUSE THE CONTRIBUTIONS ARE FROM RELATED ORGANIZATIONS, GOVERNMENT GRANTS, AND OTHER GRANTS. H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION, INC. HANDLES ALL FUNDRAISING ACTIVITIES FOR H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. AND ITS SUBSIDIARIES. FORM 990, PART XI, LINE 9: CHANGES IN NET ASSETS PREDOMINANTLY RELATES TO THE CLOSE OUT OF INTERCOMPANY ACCOUNTS PAYABLE AND RECEIVABLES (DUE TO/DUE FROM) IN THE AMOUNT OF $179,024,031 TO NET ASSETS. H LEE MOFFITT CANCER CTR & RESEARCH INSTITUTE HOSPITAL INC 12902 MAGN0LIA DRIVE TAMPA FL 33612 593238634 PATIENT CARE FL 501(C)(3) LINE 3 N/A 1 H LEE MOFFITT CANCER CTR & RESEARCH INSTITUTE FOUNDATION INC 12902 MAGN0LIA DRIVE TAMPA FL 33612 593238636 FUNDRAISING FL 501(C)(3) LINE 7 H LEE MOFFITT CANCER CTR & RES INST INC 1 H LEE MOFFITT CC&RI LIFETIME CANCER SCREENING CENTER INC 12902 MAGN0LIA DRIVE TAMPA FL 33612 593238640 PRACTICE MANAGEMENT FL 501(C)(3) LINE 10 H LEE MOFFITT CANCER CTR & RES INST INC 1 MOFFITT TECHNOLOGIES CORPORATION 12902 MAGNOLIA DRIVE TAMPA FL 33612 300332914 TECHNOLOGY MANAGEMENT FL H LEE MOFFITT CC&RI INC C 1176 260908 1.00000 1 M2GEN CORP 10902 N MCKINLEY DRIVE TAMPA FL 33612 208486180 DATABASE MANAGEMENT FL H LEE MOFFITT CC&RI INC C -891894 50996529 0.67300 1 ONCOBAY CLINICAL INC 10902 N MCKINLEY DRIVE TAMPA FL 33612 843412796 RESEARCH & PRODUCT DEVELOPMENT FL H LEE MOFFITT CC&RI INC C -776654 466603 1.00000 1 1 1 1 0 0 0 0 0 0 0 1 1 1 1 0 1 0 0 1 M2GEN CORP B 47942 FMV H LEE MOFFITT CC&RI HOSPITAL INC B 29915 FMV H LEE MOFFITT CC&RI HOSPITAL INC C 7680013 FMV H LEE MOFFITT CC&RI FOUNDATION INC C 22556958 FMV M2GEN CORP S 1606275 FMV H LEE MOFFITT CC&RI FOUNDATION INC P 5333586 FMV M2GEN CORP P 413002 FMV M2GEN CORP L 1817317 FMV ONCOBAY CLINICAL INC P 144235 FMV ONCOBAY CLINICAL INC A 5200 FMV ONCOBAY CLINICAL INC A 73597 FMV